Pharmacology of Trekrezan, a new immune modulator and adaptogen
P. D. Shabanov, I. V. Zarubina, E. V. Mokrenko · 2014 · Reviews on Clinical Pharmacology and Drug Therapy 12(2):12–27
What does this source report?
Reviews immune, inflammatory and metabolic mechanisms, including Trekrezan/Metaprot combinations in rat models.
- Population and setting
- Review of experimental pharmacology
- Evidence type
- Review
- Preparation
- See the original report; formulation details require verification.
- Source language
- Russian; English abstract where indicated
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Review and originating-group synthesis; not a new human trial.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Citation and available abstract or selected source passages checked; complete methods and risk-of-bias appraisal pending.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Open original source or index record ↗
DOI: 10.17816/RCF12212-27
Cite and trace this record
Original source: P. D. Shabanov, I. V. Zarubina, E. V. Mokrenko. Pharmacology of Trekrezan, a new immune modulator and adaptogen Reviews on Clinical Pharmacology and Drug Therapy 12(2):12–27 2014.
Molekul research summary: https://molekul.io/research/trek-review-2014. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry